130
Participants
Start Date
June 30, 2006
Primary Completion Date
February 28, 2009
Study Completion Date
January 31, 2010
Bortezomib
Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
Graz
Oberpullendorf
Vienna
Antwerp
Brussels
Ghent
Roeselare
Dijon
Limousis
Marseille
Nantes
Paris
Pessac
Bad Soden
Berlin
Cologne
Erlangen
Hamburg
Hamm
Hanover
Kiel
Mainz
Würselen
Athens
Pátrai
Thessalonikis
Luxembourg
Almada
Coimbra
Lisbon
Barcelona
Cadiz
Málaga
Salamanca
Santiago de Compostela
Seville
Toledo
Zaragoza
Lead Sponsor
Janssen-Cilag International NV
INDUSTRY